Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Novo Nordisk Raises Sales Outlook on Soaring Demand for Ozempic and Wegovy
12:29pm, Friday, 13'th Oct 2023
Novo Nordisk now expects 2023 sales growth of between 32% and 38%.
What exactly are patients taking new weight-loss drugs eating and what are they avoiding? Bernstein asked them.
11:34am, Friday, 13'th Oct 2023
Bernstein analysts set out to determine that, analyzing online data to better understand changes in eating habits — and to evaluate which food companies may be most affected. They published the resu
Novo Nordisk hikes outlook on soaring demand for Wegovy, Ozempic
11:05am, Friday, 13'th Oct 2023
Novo Nordisk's forecast only confirms the frenzy for Wegovy and Ozempic, which patients seek for their ability to help them lose significant weight over time.
Novo Nordisk ups guidance, sees higher sales of Ozempic
10:19am, Friday, 13'th Oct 2023
Novo Nordisk (NYSE:NVO)'s shares have jumped after it lifted annual guidance, predicting a boost from higher sales of its diabetes drug Ozempic in the US. Europe's most valuable company, after recent
Novo Nordisk boosts sales and profit outlook, buoyed by Ozempic and Wegovy
09:08am, Friday, 13'th Oct 2023
Novo Nordisk NVO, +1.36% on Friday boosted its full-year 2023 profit and sales outlook, reflecting heightened expectations for Ozempic and Wegovy sales. The company now projects full-year sales growth
Novo Nordisk raises outlook for full-year sales, operating profit
08:54am, Friday, 13'th Oct 2023
Novo Nordisk has raised the outlook for its full-year sales and operating profit, the Danish drugmaker said in a statement on Friday.
1 Dividend Legend Potentially Set To Soar And 2 To Ignore
07:25am, Friday, 13'th Oct 2023
1 Dividend Legend Potentially Set To Soar And 2 To Ignore
Will Higher Ozempic Use Mean Slimmed-Down Food Sales?
08:01am, Thursday, 12'th Oct 2023
But does Novo Nordisk's good fortune translate to lower sales for companies like Walmart Inc. NYSE: WMT, Coca-Cola Co. NYSE: KO and PepsiCo Inc. NASDAQ: PEP?
Novo Nordisk warns online offers of fake Ozempic, Wegovy are on the rise
07:15am, Thursday, 12'th Oct 2023
Novo Nordisk on Thursday warned of a surge in counterfeit versions of its weight-loss drug Wegovy and diabetes drug Ozempic offered online as illegal traders seek to take advantage of their huge popul
7 Affordable Stocks to Invest in as America's Population Ages
06:00am, Thursday, 12'th Oct 2023
There's no doubt that America is aging. The numbers do not lie.
Australia's CSL tanks as Novo Nordisk's kidney trial success stokes competition concerns
01:54am, Thursday, 12'th Oct 2023
Shares of biotechnology firm CSL fell to a four-year low on Thursday, after rival Novo Nordisk's Ozempic drug showed early signs of success in delaying the progression of kidney disease in diabetes pa
Novo Nordisk stock pops on Ozempic kidney trial success
04:58pm, Wednesday, 11'th Oct 2023
Shares of Novo Nordisk (NVO) rose on Wednesday after the drugmaker announced it was stopping a trial because early results show its popular diabetes drug Ozempic was effective in treating failure. The
The 3 Widest Competitive Moats on Wall Street
03:48pm, Wednesday, 11'th Oct 2023
Competitive moats symbolize a company's sustainable advantage, protecting it from competitors and external threats. Three standout examples illustrate this principle vividly.
Ozempic Study Shakes Up Market for Kidney and Insulin Treatments
01:05pm, Wednesday, 11'th Oct 2023
American depositary receipts (ADRs) of Novo Nordisk (NOVO) jumped over 6% in early trading on Wednesday, while shares of kidney dialysis machine and insulin pump makers tumbled, after the drug maker h
Novo Nordisk stops Ozempic trial early after signs of early success
12:28pm, Wednesday, 11'th Oct 2023
CNBC's Angelica Peebles reports on news from Novo Nordisk.
